0 25

Cited 0 times in

Soluble Siglec-9 alleviates intestinal inflammation through inhibition of the NF-κB pathway

DC FieldValueLanguage
dc.contributor.author강은애-
dc.date.accessioned2020-12-01T16:51:27Z-
dc.date.available2020-12-01T16:51:27Z-
dc.date.issued2020-09-
dc.identifier.issn1567-5769-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180010-
dc.description.abstractBackground: Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a superfamily of immunoreceptors recognizing sialic acid. Siglec-9 has been shown to mediate inhibitory immune responses. The aim of this study was to evaluate the effect of a soluble form of Siglec-9 (sSiglec-9) on inflamed intestinal epithelial cells (IECs), murine macrophages, and experimental murine colitis models. Methods: COLO 205 human IECs and RAW 264.7 murine macrophages were pretreated with sSiglec-9 and then stimulated with TNF-α or lipopolysaccharides, respectively. The expression of proinflammatory cytokines such as IL-8 and TNF-α was measured using real-time RT-PCR and ELISA. To demonstrate the inhibitory effects of sSiglec-9 on the NF-κB pathway, IκBα phosphorylation/degradation was determined using western blotting and the DNA binding activity of NF-κB was evaluated using an electrophoretic mobility shift assay. Further, mouse models with dextran sulfate sodium-induced acute colitis and piroxicam-induced IL-10-/- chronic colitis were generated. Intraperitoneal injections of sSiglec-9 were performed, and body weight, colon length, and histopathologic findings were examined. Results: sSiglec-9 suppressed IL-8 and TNF-α gene expression in stimulated COLO 205 and RAW 264.7 cells. sSiglec-9 inhibited IκBα phosphorylation/degradation and the DNA binding activity of NF-κB. sSiglec-9 injections significantly ameliorated weight loss, colon shortening, and the severity of intestinal inflammation in acute and chronic colitis mouse models. Conclusion: sSiglec-9 may inhibit NF-κB activation in IECs and macrophages and alleviate experimental colitis in mice, suggesting that sSiglec-9 is a potential therapeutic agent for the treatment of inflammatory bowel disease.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Science-
dc.relation.isPartOfINTERNATIONAL IMMUNOPHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleSoluble Siglec-9 alleviates intestinal inflammation through inhibition of the NF-κB pathway-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorEun Ae Kang-
dc.contributor.googleauthorHosim Soh-
dc.contributor.googleauthorSeona Park-
dc.contributor.googleauthorHyun Jung Lee-
dc.contributor.googleauthorJong Pil Im-
dc.contributor.googleauthorJoo Sung Kim-
dc.identifier.doi10.1016/j.intimp.2020.106695-
dc.contributor.localIdA05966-
dc.relation.journalcodeJ01081-
dc.identifier.eissn1878-1705-
dc.identifier.pmid32570035-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S1567576920310031-
dc.subject.keywordExperimental colitis-
dc.subject.keywordInflammatory bowel diseases-
dc.subject.keywordNF–κB-
dc.subject.keywordSiglec–9-
dc.contributor.alternativeNameKang, Eun Ae-
dc.contributor.affiliatedAuthor강은애-
dc.citation.volume86-
dc.citation.startPage106695-
dc.identifier.bibliographicCitationINTERNATIONAL IMMUNOPHARMACOLOGY, Vol.86 : 106695, 2020-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.